Please Wait.....
Report
Psoriatic Arthritis - Epidemiology Forecast - 2032
Market Report I 2022-09-01 I 141 Pages I DelveInsight
DelveInsight's 'Psoriatic Arthritis (PsA) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of psoriatic arthritis (PsA) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Psoriatic Arthritis (PsA): Disease Understanding
Psoriatic Arthritis (PsA) Overview
Psoriatic arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin and nail disease characterized by red, scaly rashes and thick pitted fingernails. Psoriatic arthritis (PsA) resembles rheumatoid arthritis (RA) in symptoms characterized by joint inflammation. However, psoriatic arthritis (PsA) affects fewer joints than RA and does not produce the typical RA antibodies.
In 1956, Wright described arthritis associated with psoriasis. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of psoriatic arthritis (PsA) is poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.
The etiology and pathogenesis of psoriatic arthritis (PsA) involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33-50% of PsA patients have at least one first-degree relative with psoriasis or psoriatic arthritis (PsA). Genes associated with psoriatic arthritis (PsA) include those in the HLA region involved in antigen presentation and immune recognition and non-HLA genes involved in immune activation and inflammation, including intracellular signaling, cytokine expression, and signaling T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma induces psoriatic skin lesions flares, known as the Koebner phenomenon. Evidence suggests that joint trauma may cause a flare of arthritis, referred to as the "internal" or "deep" Koebner phenomenon.
Psoriatic arthritis (PsA) shares some clinical features with other inflammatory arthritides, including RA, reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnosis. Unlike psoriatic arthritis (PsA), RA is symmetrical and generally spares the DIP joints. AS has an earlier onset age than psoriatic arthritis (PsA), and sacroiliac involvement is usually symmetric rather than asymmetric.
Psoriatic arthritis (PsA) may range from mild to severe, and its treatment is crucial despite the severity. If left untreated, psoriatic arthritis (PsA) can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating psoriatic arthritis (PsA) may also help reduce inflammation that could lead to other comorbidities. However, no cure for psoriatic arthritis (PsA) exists, so treatment goals are to slow disease progression, improve QoL, lessen pain, and preserve the range of motion. In most PsA patients, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs, if a patient does not respond adequately.
Epidemiology
Psoriatic arthritis (PsA) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted psoriatic arthritis (PsA) epidemiology segmented as the prevalent cases of psoriatic arthritis (PsA), diagnosed cases of psoriatic arthritis (PsA), gender-specific cases of psoriatic arthritis (PsA), age-specific cases of psoriatic arthritis (PsA) and severity-specific cases of psoriatic arthritis (PsA). The report includes the prevalent psoriatic arthritis (PsA) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country-wise psoriatic arthritis (PsA) Epidemiology
The epidemiology segment also provides psoriatic arthritis (PsA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 1.5 million in 2021.
As per the estimates, the US had the highest total patient population of psoriatic arthritis (PsA) in 2021. Among the EU5 countries, Spain had the highest total prevalent patient population of psoriatic arthritis (PsA), with more than 200,000 cases, followed by Italy in 2021. On the other hand, France had the lowest total prevalent patient population of psoriatic arthritis (PsA), close to 53,000 cases in 2021.
Scope of the Report
- Psoriatic arthritis (PsA) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
- Psoriatic arthritis (PsA) epidemiology report and model provide an overview of the risk factors and global trends of psoriatic arthritis (PsA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into the historical and forecasted patient pool of psoriatic arthritis (PsA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of psoriatic arthritis (PsA).
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by prevalent cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by diagnosed cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by age-specific cases of psoriatic arthritis (PsA) in the 7MM.
- The report provides the segmentation of psoriatic arthritis (PsA) epidemiology by gender-based cases of psoriatic arthritis (PsA) in the 7MM.
- The report segments psoriatic arthritis (PsA) epidemiology by severity-specific cases of psoriatic arthritis (PsA) in the 7MM.
Report Highlights
- 11-year forecast of psoriatic arthritis (PsA) epidemiology
- 7MM coverage
- Prevalent cases of psoriatic arthritis (PsA)
- Diagnosed cases of psoriatic arthritis (PsA)
- Age-specific cases of psoriatic arthritis (PsA)
- Gender-specific cases of psoriatic arthritis (PsA)
- Severity-specific cases of psoriatic arthritis (PsA)
KOL Views
We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.
Key questions answered
- What are the major factors that will drive the change in the patient population in psoriatic arthritis (PsA) during the forecast period (2019-2032)?
- What are the key findings pertaining to psoriatic arthritis (PsA) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients with psoriatic arthritis (PsA) across the 7MM during the forecast period (2019-2032)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
- What are the disease risk, burdens, and unmet needs of psoriatic arthritis (PsA)?
- What are the currently available treatments for psoriatic arthritis (PsA)?
Reasons to buy
Psoriatic Arthritis (PsA) epidemiology report will allow the user to:
- Develop business strategies by understanding the trends shaping and driving the global psoriatic arthritis (PsA) market
- Quantify patient populations in the global psoriatic arthritis (PsA) market to improve product design, pricing, and launch plans
- Understand the magnitude of psoriatic arthritis (PsA) population by its prevalent cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its diagnosed cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its age-specific cases
- Understand the magnitude of psoriatic arthritis (PsA) population by its gender-specific cases of psoriatic arthritis (PsA)
- Understand the magnitude of psoriatic arthritis (PsA) population by its severity-specific cases of psoriatic arthritis (PsA)
- Psoriatic arthritis (PsA) epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- Psoriatic arthritis (PsA) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
?
Key Assessments
- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. Psoriatic Arthritis Market Overview at a Glance
3.1. Market Share (%) Distribution of PsA in 2019
3.2. Market Share (%) Distribution of PsA in 2032
4. Executive Summary of Psoriatic Arthritis
5. Disease Background and Overview
5.1. Introduction
5.2. Clinical Manifestations
5.3. Classification
5.4. Risk Factors
5.5. Pathogenesis
5.6. Diagnosis
5.7. Differential Diagnosis
5.8. Treatment and Management
5.8.1. ACR/NPF Recommendations for PsA
5.8.2. Summary of differences in recommendations
5.8.3. EULAR Recommendations
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Prevalence of PsA in the 7MM
6.3. Assumption and Rationale
6.4. The United States
6.4.1. Prevalent cases of PsA in the United States
6.4.2. Diagnosed Cases of PsA in the United States
6.4.3. Gender-specific Cases of PsA in the United States
6.4.4. Age-specific Cases of PsA in the United States
6.4.5. Severity-specific Cases of PsA in the United States
6.5. EU5
6.5.1. Total Prevalent Cases of PsA in the EU5
6.5.2. Germany
6.5.2.1. Diagnosed Cases of PsA in Germany
6.5.2.2. Gender-specific Cases of PsA in Germany
6.5.2.3. Age-specific Cases of PsA in Germany
6.5.2.4. Severity-specific Cases of PsA in Germany
6.5.3. France
6.5.3.1. Diagnosed Cases of PsA in France
6.5.3.2. Gender-specific Cases of PsA in France
6.5.3.3. Age-specific Cases of PsA in France
6.5.3.4. Severity-specific Cases of PsA in France
6.5.4. Italy
6.5.4.1. Diagnosed Cases of PsA in Italy
6.5.4.2. Gender-specific Cases of PsA in Italy
6.5.4.3. Age-specific Cases of PsA in Italy
6.5.4.4. Severity-specific Cases of PsA in Italy
6.5.5. Spain
6.5.5.1. Diagnosed Cases of PsA in Spain
6.5.5.2. Gender-specific Cases of PsA in Spain
6.5.5.3. Age-specific Cases of PsA in Spain
6.5.5.4. Severity-specific Cases of PsA in Spain
6.5.6. The United Kingdom
6.5.6.1. Diagnosed Cases of PsA in the UK
6.5.6.2. Gender-specific Cases of PsA in the UK
6.5.6.3. Age-specific Cases of PsA in the UK
6.5.6.4. Severity-specific Cases of PsA in the UK
6.6. Japan
6.6.1. Prevalent cases of PsA in Japan
6.6.2. Diagnosed Cases of PsA in Japan
6.6.3. Gender-specific Cases of PsA in Japan
6.6.4. Age-specific Cases of PsA in Japan
6.6.5. Severity-specific Cases of PsA in Japan
7. Patient Journey of Psoriatic Arthritis
8. SWOT Analysis
9. KOL Views
10. Unmet Needs
11. Market Access
12. Acronyms and Abbreviations
13. Appendix
13.1. Bibliography
13.2. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
Table 1: Summary of PsA, Epidemiology, and Key Events (2019-2032)
Table 2: Role of HLA Genes in PsA
Table 3: Role of non-HLA Genes in PsA
Table 4: CASPAR Criteria
Table 5: Moll and Wright Classification
Table 6: Operational Definition of Classification of PsA
Table 7: Suggested Diagnostic Algorithm
Table 8: Clinical Characteristics of Different Types of Arthritis That can aid Differential Diagnosis
Table 9: 2018 ACR/NPF Recommendations for the Initial Treatment for Active PsA who are OSM? and Other Treatment-naive
Table 10: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With a TNFi Biologics
Table 11: 2018 ACR/NPF Recommendations for Active PsA Despite Treatment With an IL?17i or an IL?12/23i Biologics
Table 12: 2018 ACR/NPF Recommendations for PsA Including Treat?to?target, Active Axial Disease, Enthesitis, or Active IBD
Table 13: 2018 ACR/NPF Recommendations for PsA and Comorbidities, Including Concomitant Diabetes and Recurrent Serious Infections
Table 14: 2018 ACR/NPF Recommendations for Non-pharmacologic Interventions in Patients With Active PsA Regardless of Pharmacologic Treatment Status
Table 15: Summary of Differences in Recommendations
Table 16: 2019 EULAR Overarching Principles
Table 17: 2019 EULAR Recommendations for the Pharmacological Management of PsA
Table 18: Total Prevalent Cases of PsA in the 7MM in 000's (2019-2032)
Table 19: Prevalent cases of PsA in the United States in 000's (2019-2032)
Table 20: Diagnosed Cases of PsA in the United States in 000's (2019-2032)
Table 21: Gender-specific Cases of PsA in the United States in 000's (2019-2032)
Table 22: Age-specific Cases of PsA in the United States in 000's (2019-2032)
Table 23: Severity-specific cases of PsA in the United States in 000's (2019-2032)
Table 24: Prevalent Cases of PsA in the EU5 in 000's (2019-2032)
Table 25: Diagnosed cases of PsA in Germany in 000's (2019-2032)
Table 26: Gender-specific Cases of PsA in Germany in 000's (2019-2032)
Table 27: Age-specific Cases of PsA in Germany in 000's (2019-2032)
Table 28: Severity-specific cases of PsA in Germany in 000's (2019-2032)
Table 29: Diagnosed cases of PsA in France (2019-2032)
Table 30: Gender-specific Cases of PsA in France in 000's (2019-2032)
Table 31: Age-specific Cases of PsA in France in 000's (2019-2032)
Table 32: Severity-specific cases of PsA in France (2019-2032)
Table 33: Diagnosed cases of PsA in Italy in 000's (2019-2032)
Table 34: Gender-specific Cases of PsA in Italy in 000's (2019-2032)
Table 35: Age-specific Cases of PsA in Italy in 000's (2019-2032)
Table 36: Severity-specific cases of PsA in Italy in 000's (2019-2032)
Table 37: Diagnosed cases of PsA in Spain in 000's (2019-2032)
Table 38: Gender-specific Cases of PsA in Spain in 000's (2019-2032)
Table 39: Age-specific Cases of PsA in Spain in 000's (2019-2032)
Table 40: Severity-specific cases of PsA in Spain in 000's (2019-2032)
Table 41: Diagnosed cases of PsA in the UK in 000's (2019-2032)
Table 42: Gender-specific Cases of PsA in the UK in 000's (2019-2032)
Table 43: Age-specific Cases of PsA in the UK in 000's (2019-2032)
Table 44: Severity-specific cases of PsA in the UK in 000's (2019-2032)
Table 45: Prevalent cases of PsA in Japan in 000's (2019-2032)
Table 46: Diagnosed Cases of PsA in Japan in 000's (2019-2032)
Table 47: Gender-specific Cases of PsA in Japan in 000's (2019-2032)
Table 48: Age-specific Cases of PsA in Japan in 000's (2019-2032)
Table 49: Severity-specific cases of PsA in Japan in 000's (2019-2032)
Figure 1: Clinical Presentations of PsA
Figure 2: Classification of PsA
Figure 3: Risk Factors
Figure 4: Role of Obesity and Risk of Cardiovascular Comorbidities in PsA patients
Figure 5: Key cell Types and Secretion of key Inflammatory Mediators in PsA
Figure 6: Adaptive and Innate Immune Cells and Activated Pathways in PsA
Figure 7: Diagnosis of PsA
Figure 8: Radiographic Features of PsA
Figure 9: Differential Diagnosis
Figure 10: Pharmacologic, Non-pharmacologic, and Symptomatic Therapies for PsA
Figure 11: The EULAR 2019 Algorithm for Treatment of PsA With Pharmacological Non-topical Treatments
Figure 12: PsA Treatment Pathway Following Inadequate Response to DMARDs (NICE)
Figure 13: Total Prevalent Cases of PsA in the 7MM in 000's (2019-2032)
Figure 14: Prevalent cases of PsA in the United States in 000's (2019-2032)
Figure 15: Diagnosed Cases of PsA in the United States in 000's (2019-2032)
Figure 16: Gender-specific cases of PsA in the United States in 000's (2019-2032)
Figure 17: Age-specific Cases of PsA in the United States in 000's (2019-2032)
Figure 18: Severity-specific Cases of PsA in the United States in 000's (2019-2032)
Figure 19: Prevalent Cases of PsA in the EU5 in 000's (2019-2032)
Figure 20: Diagnosed cases of PsA in Germany in 000's (2019-2032)
Figure 21: Gender-specific cases of PsA in Germany in 000's (2019-2032)
Figure 22: Age-specific Cases of PsA in Germany in 000's (2019-2032)
Figure 23: Severity-specific Cases of PsA in Germany in 000's (2019-2032)
Figure 24: Diagnosed cases of PsA in France (2019-2032)
Figure 25: Gender-specific cases of PsA in France in 000's (2019-2032)
Figure 26: Age-specific Cases of PsA in France in 000's (2019-2032)
Figure 27: Severity-specific Cases of PsA in France (2019-2032)
Figure 28: Diagnosed cases of PsA in Italy in 000's (2019-2032)
Figure 29: Gender-specific cases of PsA in Italy in 000's (2019-2032)
Figure 30: Age-specific Cases of PsA in Italy in 000's (2019-2032)
Figure 31: Severity-specific Cases of PsA in Italy in 000's (2019-2032)
Figure 32: Diagnosed cases of PsA in Spain in 000's (2019-2032)
Figure 33: Gender-specific cases of PsA in Spain in 000's (2019-2032)
Figure 34: Age-specific Cases of PsA in Spain in 000's (2019-2032)
Figure 35: Severity-specific Cases of PsA in Spain in 000's (2019-2032)
Figure 36: Diagnosed cases of PsA in the UK in 000's (2019-2032)
Figure 37: Gender-specific cases of PsA in the UK in 000's (2019-2032)
Figure 38: Age-specific Cases of PsA in the UK in 000's (2019-2032)
Figure 39: Severity-specific Cases of PsA in the UK in 000's (2019-2032)
Figure 40: Prevalent cases of PsA in Japan in 000's (2019-2032)
Figure 41: Diagnosed Cases of PsA in Japan in 000's (2019-2032)
Figure 42: Gender-specific cases of PsA in Japan in 000's (2019-2032)
Figure 43: Age-specific Cases of PsA in Japan in 000's (2019-2032)
Figure 44: Severity-specific Cases of PsA in Japan in 000's (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security